Clinical Trial

BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

Study acronym: BETRI
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-01
Trial Details
NCT Number NCT07666490
Lead Sponsor Chiesi Farmaceutici S.p.A.
Conditions Asthma
Enrollment 644 participants
Start Date 2026-06-28
Primary Completion 2028-06-13 (estimated)
Study Completion 2028-06-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-31